Infusions of large numbers (>lO"/kg) of donor leukocytes can induce remissions in patients with chronic myeloid leukemia (CML) who relapse after marrow transplantation. We wanted t o determine if substantially lower numbers of donor leukocytes could induce remissions and, if so, whether this would reduce the 90% incidence of graft-versus-host disease (GVHD) associated with this therapy. Twenty-two patients with relapsed CML were studied: 2 in molecular relapse, 6 in cytogenetic relapse, 10 in chronic phase, and 4 in accelerated phase. Each patient received escalating doses of donor leukocytes at 4-t o 33-week intervals. Leukocyte doses were calculated as T cells per kilogram of recipient weight. There were 8 dose levels between 1 x lo5 and 5 x 10'. Lineage-specific chimerism and residual leukemia detection were assessed using sensitive polymerase chain reaction (PCR) methodologies. Nineteen of the 22 patients achieved remission. Remissions were achieved at the following T-cell doses: 1 x lo7 (n = 8). 5 x lo7 (n = 4). 1 x 10" (n = 3). and 5 x 10" (n = 4). To date, 15 of the 17 evaluable ONE MARROW transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukemia (CML) who have a suitable bone marrow donor. The success of allogeneic BMT is limited by the morbidity and mortality caused by graft-versus-host disease (GVHD), a complication that can be prevented by the removal of T cells from the donor marrow. A higher incidence of relapse has been reported for T-cell-depleted grafts as compared with unmanipulated BMT, suggesting that the removal of T cells from the donor marrow not only results in a lower incidence of GVHD but also in a loss of a graft-versus-leukemia (GVL) effect. ' The management of relapsed CML after T-cell-depleted BMT is difficult because cytotoxic drugs and (Y interferon (aIFN) are seldom curative' and second bone marrow transplants are associated with a high regimen-related mortality and poor survival rates? The remissions induced with the use of donor leukocyte infusions for treatment of relapsed CML initially reported by Kolb et a14 have subsequently been confirmed by other investigator^.^"^ However, this GVL effect of donor leukocytes has been associated with a 90% incidence of GVHD in patients who achieved remision.^"' The GVHD observed in the patients who received adoptive immunotherapy is assumed to be initiated by the large numbers of alloreactive donor T cells (median, > l X lO*/kg recipient weight) in the leukocyte infusion^.^"'
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We hypothesized that lower numbers of donor leukocytes might be able to mediate a GVL effect and achieve remission of relapsed CML without precipitating the high incidence of GVHD previously reported. We therefore designed a stepwise dose escalation trial to assess whether the antileukemic patients have become BCR-ABL negative by PCR. The incidence of GVHD was correlated with the dose of T cells administered. Only 1 of the 8 patients who achieved remission at a T-cell dose of 1 x 107/kg developed GVHD, whereas this complication developed in 8 of the 11 responders who received a T-cell dose of z 5 x 107/kg. Three patients died in remission, 1 secondary t o marrow aplasia, 1 of respiratory failure, and 1 of complications of chronic GVHD. Sixteen patients who were mixed T-cell chimeras before treatment became full donor T-cell chimeras at the time of remission.
Donor leukocytes with a T-cell content as low as 1 x lo7/ kg can result in complete donor chimerism together with a potent graft-versus-leukemia (GVLI effect. The dose of donor leukocytes or T cells used may be important in determining both the GVL response and the incidence of GVHD. In many patients, this potent GVL effect can occur in the absence of clinical GVHD. 0 1995 by The American Society of Hematology.
effect of donor leukocyte infusions could be achieved at T-cell doses lower than that which would induce clinical GVHD.
PATIENTS AND METHODS

Patients.
Twenty-two patients with relapsed CML after allogeneic BMT were studied. Details of the patient characteristics are shown in Table 1 . Donor-recipient pairs were matched at the human leukocyte antigen A, B, and DR loci. The patients were conditioned with 12 X 125 cGy fractionated total body irradiation + 120 m@ kg cyclophosphamide IT 10 mgkg thiotepa or 750 m@mz VP-16. All patients received a T-cell-depleted marrow graft." Clinical protocols were approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center and transplantsfleukocyte infusions were performed with the informed consent of each of the patients. Donor leukocyte treatment. No immunosuppressive drugs were administered before or after the leukocyte infusions. Nine patients (Fig 1A) . The donors underwent leukapheresis with the Fenwal CS3000 apheresis system (Baxter, Deerfield, IL). The T-cell dose administered was calculated according to the following formula: total nucleated cells X percentage CD3+ cells per kilogram of recipient weight. The percentage of CD3+ cells was determined using a fluorescein isothiocyanate (FlTC)-conjugated CD3-specific monoclonal antibody (Leu 4; Becton Dickinson, Mountain View, CA) with a FACScan cell analyzer (Becton Dickinson). There were 8 planned dose levels (T cellslkg recipient weight) on the treatment protocol: 1 X I@, 5 X l@, 1 X IO6, 5 X IO6, 1 X lo7, 5 X lo7, 1 X loa, and 5 X 10'.
The first 10 patients began treatment at a T-cell dose of 1 X IO5/ kg, a dose selected because it represents the number of clonable T cells that, if administered on the day of transplant, is able to cause GVHD.'' Because no responses were documented within 18 weeks of receipt of a T-cell dose of S 1 X 106kg, the subsequent 12 patients began treatment at a T-cell dose of 1 X 107/kg. The actual T-cell and nucleated cell doses infused together with the times of administration are shown in Table 2 . A single patient (UPN 1001) received additional donor leukocytes with a T-cell content of 1.6
X 108/kg 46 weeks after completion of the leukocyte escalation ( Fig 1A) . The time interval between doses was a compromise between allowing each dose to have sufficient time to show a GVL effect and the practical consideration of attaining remission before the patients' leukemia progressed to blast crisis. The median time interval between leukocyte dose escalations was 6 weeks (range, 4 to 33 weeks) but was only 5 weeks for patients receiving s l X 107kg and 9 weeks for patients receiving z 5 X 107/kg. Eight of the last 12 patients entered on study received only a single dose of donor leukocytes with a T-cell content of 1 X 107kg.
Evaluation of patient response. Patients were evaluated every 1 to 4 weeks after the leukocyte infusions for evidence of GVHD. Complete blood counts, serum electrolytes, and liver function tests were obtained weekly. Bone marrow aspirates were performed before starting leukocyte therapy, before each dose escalation, and at the time of clinical response to assess morphology, cytogenetics, and minimal residual disease.
Acute and chronic GVHD were classified according to standard criteria that have been previously de~cribed.'~.'~ Marrow aplasia was defined by the presence of pancytopenia (neutrophils, <500/pL; platelets, <2OlpL) in the setting of a hypocellular bone marrow.
Defiirion of remission
The results are presented as of March 3 1, 1995. Hematologic remission was defined as a return to normal blood counts and bone marrow cellularity in the absence of antileukemic therapy. Cytogenetic remission was considered to be present when all bone marrow metapbases were normal. In each case, whenever possible, at least 20 metaphases were examined. 'Ihe finding of a single Philadelphia (€'h)-positive metaphase at any time was defined as cytogenetic relapse. Patients mated for molecular relapse had to have two c o mtive positive results for polymerase chain reaction (PCR) assays for BCR-ABL mRNA from both bone marrow and peripheral blood at least 3 months apaa. Molecular remission was defined as the absence of BCR-ABL mRNA transcripts in bone marrow and peripheral blood using reverse transcriptasePCR as described below.
Molecular analysis of chimerism and residual disease. To assess chimerism, high molecular weight DNA was extracted from peripheral blood obtained from the donor and recipient before the transplant. DNA was extracted from purified peripheral blood granulocytes and T cells before and after the leukocyte infusions to allow assignment of lineagespecific chimerism, as previously de~cribed.'~"~ Minisatellite PCR was used to determine ~himerism.'~ PCR product was electrophoresed on agarose gels and, after Southern 
RESULTS
Response of CML. Nineteen of the 22 patients achieved remission. Three patients failed to respond; the 2 nonresponders treated in accelerated phase have progressed to blast crisis. The times to hematologic remission, cytogenetic remission, and molecular remission are shown in Table 3 . Remissions were achieved at the following cell doses: 1 X lo7 (n = 8), 5 x lo7 (n = 4), 1 X 10' (n = 3), and 5 X 10" (n = 4). Although we can be certain that 8 of the patients entered remission after a single dose of leukocytes with a T-cell content of 1 X 107/kg, the specific leukocyte dose or doses that resulted in remission induction in the 11 responders who received multiple leukocyte infusions cannot be identified with certainty. For example, UPN 1255 had cytogenetic evidence of response after the first dose of leukocytes with a T-cell content of 1 X 107/kg (Fig lB) , and 5 of the other 10 responders entered hematologic remission within 2 to 3 weeks of receiving their last donor leukocyte infusion ( Table 3 ), suggesting that either they had a very rapid response to the last dose of leukocytes or that their responses were mediated by the prior dose or doses of donor leukocytes.
Three patients with hematologic relapse had delayed responses (74 to 108 weeks) to the donor leukocytes infusions. All 3 of these patients were began nIFN therapy after initially failing to respond to donor leukocytes alone. UPN 1105 began aIFN therapy at the time of the final leukocyte infusion, whereas UPNs 1001 and 1209 received nIFN 22 and 18 weeks after a failure to respond to donor leukocytes with a T-cell content of 3.6 to 5 X 108/kg (Fig 1A) .
Serial cytogenetic studies performed before and after donor leukocyte infusions showed the disappearance of the Ph chromosome in responders who had hematologic or cytogenetic relapse (Fig l) . With the exception of UPNs 11 18 and 1447, all patients had evidence of residual leukemia on PCR analysis at the time of documented cytogenetic remission. Fifteen of the 17 evaluable patients have become PCR negative for BCR-ABL mRNA at 12 to 37 weeks after their last donor leukocyte infusion (Fig 1) . Chimerism. The results of the PCR studies to detect chimerism are summarized in Table 3 . Twenty patients were mixed T-cell chimeras before the donor leukocyte treatment. At each dose level at which the patients' leukemia did not go into remission, the T cells remained mixed chimeric; however, on entering remission, the host T cells were no longer detectable (Fig 2) . After remission induction, all responders had granulocytes exclusively of donor origin (Fig  2) . Sixteen of the 17 responders who were mixed T-cell chimeras before treatment became full donor T-cell chimeras on entering remission. There was no change in myeloid or T-cell chimerism in the nonresponders.
Toxicity. There were 3 treatment-related mortalities. One patient (UPN 1562) developed marrow aplasia and received a T-cell-depleted donor marrow boost but died of sepsis within 14 days of marrow infusion without evidence of engraftment. the lung showed adult respiratory distress syndrome with no evidence of lymphocytic infiltration. The third death (UPN 546) was secondary to complications of chronic GVHD. A fourth patient (UPN 137 I ) who had received a splenectomy before transplant and who was noncompliant with his penicillin prophylaxis died in chronic phase of pneumococcal sepsis.
The relationship between the dose of T cells administered and the incidence of GVHD observed is shown in Table 4 .
As can be seen, no patient developed GVHD after leukocyte infusions containing T-cell doses 4 X 106kg. Of the 21 patients who received the T-cell dose of 1 X IO'kg, only one (UPN 1376) developed limited chronic GVHD. Fourteen patients received leukocyte infusions with a T-cell dose of 2 5 X 107/kg and 8 developed chronic GVHD. The commonest presentation of chronic GVHD was oral mucositis, which was seen in 6 of the 9 patients. Chronic GVHD was treated with corticosteroid therapy t azathioprine or cyclosporine A. One patient developed grade I1 acute GVHD after a leukocyte infusion with a T-cell content of 1 X IOx/ kg.
DISCUSSION
In this study we have shown that the number of donor leukocytes administered to patients with relapse of CML after BMT may be important in mediating a GVL response.
In contrast to previous studies in which the median dose of donor leukocytes administered to patients was 3.8 X IO%g (range, 0.34 to 12.3 X 10xkg)?"' this report has clearly shown that donor leukocytes with a T-cell content of only I X 107kg are capable of inducing remissions. These are the lowest numbers of donor leukocytes that have ever been documented to induce remissions in patients with CML who relapse after BMT.
Although donor leukocyte therapy has resulted in a remission rate in excess of 70% in patients with relapse of CML after BMT, it has been associated with a significant morbidity and mortality."' The major toxicities of this treatment are secondary to marrow aplasia and GVHD, which may occur in up to 50% and 90% of responders, respectively.'""' The low incidence of GVHD seen in this report may be a related to the relatively low number of donor leukocytes that were used to achieve remission because the majority of our patients received fewer leukocytes than in most other studies:"" In support of this concept was the absence of either acute or chronic GVHD seen in 7 of 8 of our patients who achieved remission after receiving a single dose of leukocytes with a T-cell content of 1 X IO7kg ( Table 4) . In previous studies, patients who were not receiving immunosuppression had a median time interval from receiving a single treatment course of donor leukocyte infusion therapy to cytogenetic remission of 13 weeks (range, 4 to 34 week^).^,^"' In our study, the 8 patients who responded to the single dose of donor leukocytes with a T- and 88 weeks, respectively, from receiving donor leukocytes with a T-cell content of 1 X 107kg to cytogenetic remission. Therefore, either these patients had a markedly delayed response to the 1 X IO'kg cell dose or they obtained their remissions from the higher doses of donor leukocytes they subsequently received. In addition, I O of our patients began dose escalation at 1 X l @ T cellskg, with 8 of them ultimately achieving cytogenetic remission. In these 8 patients, Therefore, either these patients responded to donor leukocytes with a T-cell content of 5 1 X 106/kg and include the slowest responders ever documented or these donor leukocyte doses are in most patients insufficient to mediate a GVL effect. These data suggest that either low doses of donor leukocytes are associated with a delayed GVL response or there is a relationship between donor leukocyte dose and response to adoptive immunotherapy.
The factors that determine which patients will achieve remission with donor leukocytes, and at what dose, are currently unknown. One factor might be the alloreactivity in the graft-versus-host direction and therefore a function of the different frequencies of alloreactive precursors seen among HLA-identical donor-recipient sibling Secondly, it has been suggested by other groups that the phase of CML or the size of the tumor cell burden could be a predictor of r e s~o n s e .~ Our data, although not statistically significant, would tend to support this hypothesis. Whereas only 2 of 4 accelerated-phase patients achieved remission, 9 of 10 chronic-phase patients and all 8 patients with cytogenetic or molecular relapse responded. In addition, there was also a suggestion that patients with chronic-or accelerated-phase disease required more donor leukocytes to achieve remission. However, we have previously shown that 2 patients with only molecular evidence of relapse of CML when receiving donor leukocytes with a T-cell content of less than 1 X IO%g used to successfully treat Epstein-Barr virus (EBV) lymphoproliferative disease ultimately had hematologic relapse 45 and 52 weeks after adoptive irnmun~therapy.'~ Thirdly, the role of aIFN in potentiating the effect of donor leukocytes remains unclear. Our data clearly show that most patients do not require aIFN to respond to donor leukocyte therapy; however, the responses seen in UPNs 1001 and 1209 suggest that IFN may be essential for remission induction in some patients. Lastly, the time interval from BMT to donor leukocyte infusion might be an important variable. We had previously shown that as few as 1 X 105/kg T cells are capable of causing GVHD if administered on the day of transplant.'* This study has shown that most patients can receive as many as 1 X 107/kg T cells 2 9 months after T-cell-depleted BMT without the development of clinical GVHD. This difference in the dose of T cells required to initiate GVHD late after transplant is analogous to the observations reported in murine models of allogeneic BMT.".*' Whether the same number of donor leukocytes could be administered without toxicity after a T-replete BMT is currently not known. It is therefore possible that a certain threshold number of donor T cells is necessary to obtain a GVL effect and that this threshold might be determined by a number of factors including time from BMT, donor-recipient alloreactivity, and disease status of the CML.
We have shown that mixed T-cell chimerism after BMT for CML is associated with the persistence of minimal residual disease and with cytogenetic or hematologic relapse.16 Because the T cell is not usually part of the leukemic clone in CML,Zh-B the persistence of host T cells after transplant is a variable that is independent of detecting residual leukemia. Our findings of a switch from mixed T-cell chimerism to all donor T-cell chimerism in patients achieving remission of CML are similar to the results of the studies of Johnson et al,25 who have shown, in a murine model, that delayed infusion of donor spleen cells after a T-cell-depleted marrow graft resulted in a conversion from mixed to full-donor T-cell chimerism together with a significant GVL effect. The finding that the donor leukocytes not only eradicate the host leukemia but also the host nonleukemic T cells suggests that the effector cells may not be leukemia-specific but, rather, are more likely allo-specific. However, these data do not preclude the possibility that other immunocompetent mediators, such as natural killer cells, which have been shown to have in vitro anti-CML activity, could play a role in the GVL re~ponse.~'
Our data indicate that patients treated for cytogenetic or molecular relapse of CML may achieve remission with little or no toxicity when receiving donor leukocytes with a Tcell content of 1 X 107/kg. This finding, if confirmed in a larger group of patients, may not only alter the way in which patients with post-BMT relapse of CML receive adoptive immunotherapy but could also change the way in which transplantation is used to cure this disease. One approach would be to offer patients a T-cell-depleted BMT with its low incidence of GVHD and transplant-related mortality. Knowing that many of these patients would relapse without intervention,' regular follow-up with PCR would be performed to detect residual CML. Adoptive immunotherapy with donor leukocytes would then be administered to patients who became PCR positive to achieve molecular remission. This might be a particularly useful approach in older patients who have the highest morbidity and mortality from GVHD and who constitute the majority of patients with CML.3' In summary, donor leukocyte infusions can induce remissions in patients with relapsed CML after BMT. The dose of donor leukocytes used may to be important for determining both GVL and GVHD. Remission induction is accompanied by switch from mixed T-cell chimerism to having T cells exclusively of donor origin. The GVL activity of these leukocytes is possibly mediated, at least in part, by alloreactive donor T cells.
